Three Pharmaceutical Markets Project Strong Growth Through 2031-2032

Three separate market research reports project substantial growth across pharmaceutical and biotechnology sectors through the early 2030s, driven by rising chronic disease prevalence and technological innovation.

The CAR T-cell therapy market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The North America CAR T-cell therapy market accounted for a 67.7% revenue share in 2025. The growing prevalence of hematologic malignancies and solid tumors is a primary driver for the CAR T-cell therapy market. Additionally, ongoing advancements in CAR T-cell technology, including improvements in CAR design, vector delivery systems, and manufacturing processes, enhance therapy efficacy, safety, and scalability.

By product, the YESCARTA segment is expected to dominate the market, with a share of 25.3% in 2025. Gilead Sciences gained a significant first-mover advantage in 2017 through Yescarta, building strong commercialization expertise and market presence. Its robust clinical profile, featuring high response rates and durable remissions, has fueled market growth in patients with relapsed or refractory large B-cell lymphoma.

The CD19 segment accounted for the largest share of the CAR T-cell therapy market in 2025, with a share of 62.3%. Bristol Myers Squibb expanded Breyanzi's FDA approval in 2024 to chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Building on the initial success of CD19 CAR T-cell therapies in treating acute lymphoblastic leukemia (ALL) and large B-cell lymphoma, research into adult leukemias has advanced. This broadening of indications for mantle cell lymphoma (MCL) and other hematologic malignancies is expected to expand the patient pool for CAR T-cell therapy.

In 2025, B-cell lymphoma dominated the CAR T-cell therapy market due to its high prevalence as the most common malignant lymphoma and significant rates of relapse or refractoriness, creating substantial unmet need. Multiple approved CD19-targeted therapies, such as Yescarta and Breyanzi, have demonstrated robust clinical efficacy, including durable remissions. The adult demographic segment accounted for the largest share of the CAR T-cell therapy market in 2025, primarily due to higher disease prevalence in adults for key indications such as large B-cell lymphoma and multiple myeloma, compared to rarer pediatric cases.

Hospitals accounted for the largest share of the CAR T-cell therapy market in 2025. The dominant share of this segment can primarily be attributed to collaborations between pharmaceutical companies and hospitals, which effectively facilitate the delivery of CAR T-cell therapies to patients.

The US pharmaceutical drug delivery market is projected to grow from USD 0.94 billion in 2026 to reach USD 1.24 billion by 2031, at a CAGR of 5.8% during the forecast period. One of the primary factors driving the expansion is the increasing prevalence of chronic diseases, the growing adoption of biologics and complex treatments, and the rising trend towards more convenient and self-administered medications.

The growing prevalence of chronic conditions highlights the need for modern drug delivery systems, such as lipid nanoparticles, autoinjectors, inhalers, transdermal patches, and controlled-release formulations. These systems are essential for supporting advanced therapies, including mRNA-based treatments, cell and gene therapies, as well as the application of peptides and other large-molecule drugs. These technologies are tailored to secure drugs during their transit, to make doses precise and efficient, and to eventually provide patients with better health effects.

The injectable drug delivery segment is expected to witness rapid growth, mainly due to the fast-paced development of biologics, biosimilars, peptide therapies, monoclonal antibodies, and mRNA-based treatments. These therapies almost entirely depend on parenteral routes due to their poor oral bioavailability and sensitivity to gastrointestinal tract degradation. Market growth is also supported by innovations such as autoinjectors, prefilled syringes, needle safety systems, depot injections, and on-body wearable injectors that improve dosing accuracy, reduce contamination risks, and enhance patient comfort.

The cancer segment is one of the fastest-growing indication segments in the US pharmaceutical drug delivery market. Growth is mainly driven by the increasing incidence of cancer, the growing acceptance of targeted therapies, and the implementation of personalized medicine practices. Recent advancements in delivery systems have introduced various methods, including injectable, implantable, and localized options such as long-acting depots, on-body injectors, nanoparticle carriers, and liposomal formulations. These innovations allow for greater concentrations of therapeutics to be delivered directly to tumors, thereby reducing side effects.

The home care settings segment is the fastest-growing segment in the US pharmaceutical drug delivery market. This trend is caused by the shift from hospital-centered care models to outpatient and home treatment models. The growing use of self-administration devices is due to factors such as rising healthcare costs, patient preference for convenience, and the expansion of telemedicine.

The market still encounters challenges related to the very high cost of developing and manufacturing intricate drug-device combination products and high-end formulations. The technology used to deliver these drugs goes through a very stringent quality control process and requires specialized materials and sophisticated device technologies, which make research and development longer and more expensive. Meanwhile, the approval process for combination products has become even more rigorous due to the increased testing requirements for safety, usability, and device performance.

The healthcare nanotechnology market is projected to reach US$ 562.4 billion by 2032. Healthcare nanotechnology, also known as nanomedicine, involves the use of nanoscale materials and devices to enhance medical applications. Technologies such as nanoparticles, nanorobots, and nano-engineered drug delivery systems are being increasingly used to improve therapeutic effectiveness, diagnostic accuracy, and treatment outcomes.

Nanomedicine enables targeted drug delivery, improved imaging technologies, enhanced bioavailability, and reduced side effects, making it a promising solution for treating complex diseases such as cancer, neurological disorders, cardiovascular diseases, and infectious conditions. One of the major factors driving growth in the healthcare nanotechnology market is the rising global prevalence of chronic diseases. Conditions such as cancer, diabetes, and cardiovascular diseases require advanced treatment strategies, and nanotechnology-based therapies offer improved precision and treatment efficiency.

Another key driver is the increasing adoption of precision medicine and minimally invasive treatments. Nanotechnology allows targeted delivery of drugs directly to diseased cells, minimizing damage to healthy tissues and improving therapeutic outcomes. Furthermore, government funding and investments in nanotechnology research are accelerating innovation. Collaborations between pharmaceutical companies, biotechnology firms, and academic institutions are supporting the development and commercialization of advanced nanomedicine solutions.

Despite strong growth potential, the healthcare nanotechnology market faces several challenges. The high cost of research, development, and manufacturing of nano-based therapies and devices remains a significant barrier. Regulatory uncertainties also pose challenges, as there are currently limited standardized frameworks for evaluating the safety and effectiveness of nanomaterials used in healthcare applications. In addition, concerns regarding the long-term toxicity and environmental impact of certain nanomaterials continue to raise ethical and regulatory questions.

Several emerging trends are shaping the future of the healthcare nanotechnology market. One major trend is the development of theranostics, which combines diagnostic imaging and therapy within a single nanoplatform. This approach allows physicians to detect diseases early while simultaneously delivering targeted treatment. Another important development is the growing use of nanocarriers in gene therapy and mRNA vaccines, enabling more efficient delivery of genetic materials to target cells.

Artificial intelligence and machine learning are also being integrated into nanotechnology research to optimize nanomedicine design, predict biological interactions, and accelerate drug development. Additionally, the industry is witnessing increased adoption of biodegradable and biocompatible nanomaterials, which improve safety profiles and reduce potential environmental risks.

The healthcare nanotechnology market is segmented based on type and application. By type, the market includes nanomedicine, nano medical devices, nano diagnostics, and other nano healthcare technologies. Nanomedicine represents one of the largest segments due to its growing role in targeted therapies and drug delivery systems.